Identifying symptomatic adverse events using the patient‐reported outcomes version of the common terminology criteria for adverse events in patients with non‐small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations-Reference-Cited by-同舟云学术

Identifying symptomatic adverse events using the patient‐reported outcomes version of the common terminology criteria for adverse events in patients with non‐small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations

Published:2022-12-30 Issue:5 Volume:12 Page:5494-5505
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Zhu Yanyan¹,Jean‐Baptiste Milenka²,Lenderking William R.²³^ORCID,Bell Jill A.¹,Revicki Dennis A.²,Lin Huamao M.¹,Brake Rachael¹,Reeve Bryce B.⁴^ORCID

Affiliation:

1. Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of TakedaPharmaceutical Company Limited Massachusetts Cambridge USA

2. Evidera Inc. Bethesda Maryland USA

3. Evidera Inc. Waltham Massachusetts USA

4. Duke University School of Medicine Durham North Carolina USA

Funder

Takeda Pharmaceuticals U.S.A.

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5376

Reference28 articles.

1. National Institutes of Health (NIH) NCI.Patient‐Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO‐CTCAE™).2019. Accessed March 6 2020.https://healthcaredelivery.cancer.gov/pro‐ctcae/

2. Comparison Between Patient-Reported and Clinician-Observed Symptoms in Oncology

3. Health care providers underestimate symptom intensities of cancer patients: A multicenter European study

4. Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review

5. Johnson & Johnson.Janssen announces U.S. FDA breakthrough therapy designation granted for JNJ‐6372 for the treatment of non‐small cell lung cancer.2020. Accessed October 3 2021.https://www.jnj.com/janssen‐announces‐u‐s‐fda‐breakthrough‐therapy‐designation‐granted‐for‐jnj‐6372‐for‐the‐treatment‐of‐non‐small‐cell‐lung‐cancer